Genxone (WAR:GX1) Marketable Securities: zł0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:GX1 Genxone SA WAR:GX1
69 GF Score
Price zł5.92
GF Value zł6.91
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genxone Marketable Securities?

Genxone WAR:GX1 +2.42% 69 Marketable Securities is zł0.00 Mil as of Jun. 2026. GuruFocus rates WAR:GX1 with a GF Score™ of 69/100 and a GF Value™ of zł6.91 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Genxone's Marketable Securities for the quarter that ended in Jun. 2026 was zł0.00 Mil.

Genxone  (WAR:GX1) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Genxone Marketable Securities Related Terms

Genxone Marketable Securities Historical Data

* Premium members only.

The historical data trend for Genxone's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genxone Marketable Securities Chart

Genxone Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Genxone Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WAR:GX1
69GF Score
Genxone SA WAR:GX1
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genxone Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of zł0.00 Mil mean?
Genxone (WAR:GX1) has a Marketable Securities of zł0.00 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Genxone and its competitors.
Is Genxone's Marketable Securities too high?
Genxone's current Marketable Securities is zł0.00 Mil. Overall, Genxone has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genxone's Marketable Securities compare to VRTX and REGN?
Genxone's Marketable Securities of zł0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Genxone and its competitors. Genxone's current Marketable Securities is zł0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genxone stock overvalued right now?
Based on GuruFocus' analysis, Genxone (WAR:GX1) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.91, compared to a current price of zł5.92 — trading 14.3% below its estimated fair value. The current Marketable Securities is zł0.00 Mil. Genxone's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Genxone (WAR:GX1), the current Marketable Securities is zł0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genxone (WAR:GX1) Overvalued in 2026?

Based on GuruFocus' analysis, Genxone stock appears to be undervalued. The current stock price of zł5.92 is trading 14.3% below its estimated GF Value™ of zł6.91. GuruFocus considers Genxone to be Modestly Undervalued.

Key valuation signals for WAR:GX1:

  • Marketable Securities: zł0.00 Mil
  • GF Value™: zł6.91 vs. price of zł5.92 (14.3% below fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the WAR:GX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genxone Business Description

Address Kobaltowa Street 6, Zlotniki, POL, 62002
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.
69GF Score

Get the complete analysis for WAR:GX1

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł5.92
Price
zł6.91
GF Value